Standard of care antibiotics

DRUG2 trials

Sponsors

Rebiotix Inc., University of Sydney

Conditions

Clostridium Difficile InfectionUrinary Tract Infections

Phase 2

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

CompletedNCT02589847

Rebiotix Inc.Clostridium Difficile Infection

Start: 2015-10-31End: 2019-03-31Updated: 2021-03-26

Phase 3

Fosfomycin Versus Standard of Care in Children With Antibiotic-resistant Urinary Tract Infections

RecruitingNCT05709028

University of SydneyUrinary Tract Infections

Start: 2023-08-02End: 2027-08-31Target: 300Updated: 2024-06-06

Related Papers

Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies.

2026-06-12

Integrated analysis of the safety of fecal microbiota, live-jslm in adults with recurrent <i>Clostridioides difficile</i> infection from five prospective clinical trials: an update.

2025-11-12

Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), Among Patients Exposed to Non–<i>Clostridioides difficile</i> Infection Antibiotics: Post Hoc Subgroup Analysis of a Phase 2 Open-Label Study

Open Forum Infectious Diseases2024-06-143 citations

702. Efficacy of Fecal Microbiota, Live-jslm After Receipt of Non–Clostridioides difficile Infection Antibiotics: Post Hoc Subgroup Analysis of a Phase 2 Open-Label Trial

Open Forum Infectious Diseases2023-11-27

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.

2022-10-26197 citations

S157 24-Month Sustained Clinical Response and Safety of RBX2660 in Participants With Recurrent Clostridioides difficile Infection: Subgroup Analysis

The American Journal of Gastroenterology2022-10-01

Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial

BMC Infectious Diseases2022-03-1279 citations

2822 Twelve-Month Durability of Microbiota-Based Drug RBX2660 for Preventing Clostridioides difficile Infection (CDI) Is Not Associated With Patient Demographics: Sub-Population Analysis of a Phase 2 Open-Label Study

The American Journal of Gastroenterology2019-10-01